Physician

Paul Melton Dodd, MD

According to 2025 Medicare claims, Paul Dodd, MD (NPI: 1538165113) practices hematology/oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32174-8179. Dodd is affiliated with the Complete Health Accountable Care LLC (ACO ID: D0036), participating under the REACH model.

Dodd's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,310 traditional Medicare patients, billed 558,807 HCPCS/CPT codes, and received $7,984,562 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,240 prescription claims across 699 beneficiaries totaling $9,680,822 in drug costs, led by Revlimid (Lenalidomide). DME data shows 57 claims. Open Payments data shows 62 records totaling $1,324. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $4,811,067 to $7,984,562. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,942,774 to $9,680,822. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $14,338 to $616.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,136	418,810	$4,811,067
2016	1,243	403,026	$4,674,452
2017	1,344	495,164	$6,394,414
2018	1,441	530,240	$6,970,559
2019	1,433	621,587	$7,681,786
2020	1,409	713,926	$8,965,941
2021	1,415	626,454	$8,185,228
2022	1,373	568,480	$7,967,486
2023	1,334	596,920	$7,969,253
2024	1,310	558,807	$7,984,562

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	377	2,531	$1,942,774
2016	400	3,025	$3,144,902
2017	447	3,178	$4,431,108
2018	466	3,170	$5,551,498
2019	484	3,003	$6,200,005
2020	526	3,480	$7,223,726
2021	530	3,640	$8,200,960
2022	570	3,837	$8,400,815
2023	602	3,552	$7,730,877
2024	699	4,240	$9,680,822

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	40	350	$84,015
2016	N/R	216	$47,862
2017	N/R	126	$19,664
2018	N/R	45	$4,954
2019	24	68	$7,062
2020	N/R	80	$4,691
2021	N/R	130	$7,048
2022	N/R	127	$5,572
2023	N/R	85	$14,020
2024	N/R	57	$1,076

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	724	1,914	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	369	475	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	466	823	$13
36415	Insertion of needle into vein for collection of blood sample	935	3,838	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	908	4,057	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	118	3,304	$2,078,042
Cabometyx	Cabozantinib S-Malate	41	1,230	$885,448
Jakafi	Ruxolitinib Phosphate	52	1,560	$848,036
Xtandi	Enzalutamide	55	1,650	$762,972
Brukinsa	Zanubrutinib	56	1,680	$611,500

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$534
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$301
K0001	Standard wheelchair	Y	N/R	12	$241

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$1,324	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul Melton Dodd, MD?

Tedicare shows public-source Medicare data for Paul Melton Dodd, MD (NPI 1538165113), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul Melton Dodd, MD have ACO affiliation data?

Paul Melton Dodd, MD is shown with ACO affiliation data for Complete Health Accountable Care LLC (REACH, ACO ID D0036).

What billing organization is linked to Paul Melton Dodd, MD?

Paul Melton Dodd, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Paul Melton Dodd, MD have Open Payments data?

Paul Melton Dodd, MD has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.